| P50 | author | Maarten J. Postma | Q87840199 |
| P2093 | author name string | Baudouin Standaert | |
| | Josephine Mauskopf | |
| | Olivier Ethgen | |
| | Rachel Emerson | |
| P2860 | cites work | Detection of rotavirus in the stools of infants aged 0-3 yr (study performed from July 1987 to May 1989) | Q46713497 |
| | Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries | Q47573959 |
| | Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program | Q48030944 |
| | Integer/linear mathematical programming models: a tool for allocating healthcare resources. | Q52011177 |
| | Applications of cost-benefit analysis to health care. Departures from welfare economic theory. | Q52912201 |
| | The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands | Q80539552 |
| | Cost-effectiveness analysis: developing nations left behind | Q81133719 |
| | Is There a Role for Pharmacoeconomics in Developing Countries? | Q82469993 |
| | Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries | Q84706897 |
| | Rotavirus gastroenteritis in Norway: analysis of prospective surveillance and hospital registry data | Q33494098 |
| | Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules | Q33606843 |
| | Cost effectiveness analysis in health care: contraindications | Q33812436 |
| | Global impact of rotavirus vaccines | Q34108591 |
| | Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries | Q35007325 |
| | Estimating cost-effectiveness in public health: a summary of modelling and valuation methods | Q36356288 |
| | WHO Guide for standardisation of economic evaluations of immunization programmes | Q37536433 |
| | Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries | Q37866754 |
| | Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries | Q37944318 |
| | The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis | Q38951775 |
| | Cost valuation in resource-poor settings | Q39090140 |
| | Foundations of Cost-Effectiveness Analysis for Health and Medical Practices | Q41231603 |
| | Economics of vaccines revisited | Q41885924 |
| | The evolving epidemiology of rotavirus gastroenteritis in central Portugal with modest vaccine coverage | Q42282785 |
| | Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model | Q42283589 |
| | The burden of hospitalizations and clinic visits for rotavirus disease in children aged <5 years in the Philippines | Q43634471 |
| | Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France | Q44931333 |
| | Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines | Q45352558 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1095-1108 | |
| P577 | publication date | 2014-10-21 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn? | |
| P478 | volume | 31 | |